Tempest Therapeutics Q2 FY26 net loss narrows to $5.24 million; R&D expense falls to $1.82 million - TPST News | RalliesTempest Therapeutics Q2 FY26 net loss narrows to $5.24 million; R&D expense falls to $1.82 million
T
TPST• Cash balance declines
- Cash and cash equivalents dropped to $779,000 at June 30, 2026 from $7.71 million at Dec. 31, 2025.
Senlang collaboration sets TPST-4003 timeline
- The Senlang collaboration set first TPST-4003 patient dosing for Q4 2026, with initial clinical data expected in H1 2027.
Quarterly loss narrows as R&D spending declines
- Tempest Therapeutics posted a GAAP net loss of $5.24 million, narrowing from $7.87 million a year earlier.
- Loss per share improved to $0.34 from $2.07 in the prior-year quarter.
- R&D expense fell to $1.82 million from $3.87 million, following reprioritization after the February 2026 asset acquisition.
